Limbrel

flavocoxid

(fla-vo-cox-id) ,

Limbrel

(trade name)

Classification

Therapeutic: nonopioid analgesics
Pharmacologic: flavanoids
Pregnancy Category: UK

Indications

Dietary management of osteoarthritis; considered to be a medical food product.

Action

Anti-inflammatory and analgesic properties related to inhibition of prostaglandin synthesis by inhibiting cyclo-oxygenase (not COX-2 selective) and other mediators of inflammation.

Therapeutic effects

Decreased pain/inflammation associated with osteoarthritis, with improved mobility.

Pharmacokinetics

Absorption: Some intestinal conversion prior to absorption, remainder unknown.
Distribution: Unknown.
Metabolism and Excretion: Mostly metabolized by the liver.
Half-life: Unknown.

Time/action profile (analgesic effect)

ROUTEONSETPEAKDURATION
POwithin 1–2 hrunknown12 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Obstetric / Lactation / Pediatric: Not recommended.
Use Cautiously in: History of GI bleeding.

Adverse Reactions/Side Effects

Cardiovascular

  • ↑ BP
  • ↑ in varicose veins

Gastrointestinal

  • GI upset

Dermatologic

  • psoriasis

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Oral (Adults) 250 mg every 12 hr (up to 250 mg three times daily has been used).

Availability

Capsules: 250 mg

Nursing implications

Nursing assessment

  • Assess pain (note type, location, and intensity), range of motion, degree of swelling, and stiffness in affected joints before and periodically during therapy.

Potential Nursing Diagnoses

Chronic pain (Indications)

Implementation

  • Oral: Administer flavocoxid twice daily.

Patient/Family Teaching

  • Instruct patient to take flavocoxid as directed. Do not increase does without consulting health care professional.

Evaluation/Desired Outcomes

  • Decrease in pain and stiffness, and improved mobility in patients with osteoarthritis.
Mentioned in ?
References in periodicals archive ?
Medical food currently available in the market include Axona (Accera), Limbrel, Deplin, Lofenalac, Ensure, Vasculera, and Vascazen.
M2 PHARMA-November 22, 2017-FDA Warns Consumers about Potentially Life-Threatening Health Problems Linked to Limbrel
A proprietary mixture of flavonoids (baicalin and catechin), known as flavocoxid (Limbrel) was tested against naproxen, a conventional nonsteroidal anti-inflammatory drug for the management of moderate osteoarthritis of the knees.
Flavocoxid, marketed as Limbrel in the USA, is a USFDA-regulated prescription, and it is expected to have significant therapeutic efficacy in the managing of chronic inflammation.
For example, Limbrel, a medical food from Primus Pharmaceuticals of Scottsdale, Ariz., prescribed by physicians and dispensed in pharmacies, will soon be in distribution in chosen markets in the United States.
Flavocoxid is currently available in two commercially marketed medical food products under the supervision of a qualified licensed health-care provider: Limbrel, a medical food available in 250 mg and 500 mg versions through conventional prescription pharmacy fulfillment (Primus Pharmaceuticals Inc.; Scottsdale, Arizona, US), and Arthroben, a professionally dispensed (via licensed healthcare provider practice dispensary or authorized patient-direct order from the manufacturer) medical food product also containing novel functional collagen peptides for joint health (SitoMedica, the medical foods division of Designs for Health Inc.; Suffield, Connecticut, USA).
Taking a close look at the launch of truly, innovative products, we see small to moderate sized biotech and nutritional companies investing in research and driving promotion of new products (e.g., Limbrel, Axona, Glycemx-360, Deplyn, Sentra).
A proprietary mixture of flavonoids (baicalin and catechin) known as flavocoxid (Limbrel) was tested against naproxen, a conventional non-steroidal anti-inflammatory drug for the management of moderate osteoarthritis (OA) of the knees.
First, in the medical food category, Limbrel (made and patented by Primus Pharmaceuticals, Scottsdale, AZ) is the first prescription product developed to meet the nutritional requirements of patients with osteoarthritis through dual inhibition of arachidonic acid metabolism.
Primus Pharmaceuticals, Inc., Scottsdale, AZ, recently debuted a product called Limbrel, the first prescription product developed to safely meet the nutritional requirements of patients with osteoarthritis (OA) through dual inhibition (COX + LOX) of arachidonic acid metabolism and antioxidant action.
According the company, the new product, called Limbrel, has demonstrated significant improvements in the validated OA measures of discomfort, stiffness and mobility.